Aim. To test the impact of a public health model to implement HIV pediatric care in Limited Resource Settings. Methods. A retrospective study on the clinical files of 679 Mozambican children (mean age 4.4 years; SD 3.2), has been carried out. The pediatric patients received HAART (Highly Active Anti-Retroviral Therapy) in the framework of DREAM, a nationwide public health program offering an integrated model of care to HIV patients including free-of-charge HAART and monitoring, nutritional assessment and supplementation, peer-to-peer education, active tracing of the dropped out patients. Results. HAART was started in 297 subjects out of 679. The median time of treatment was 286 (IQ 25-75:125-465). Mortality rate was lower in the sub-sample receiving HAART (8.4%; CI 95%: 5.2-11.6 vs 13.1%; CI 95%: 9.7-16.5). After 6 months of treatment the percentage of viral load lower than 400 copies/mL rose from 4.9% to 46.3%. The percentage of patients with less than 15% of CD4 cells out of the total lymphocyte count and the percentage of patients below the -2 z-score decreased from 56.4% and 58.1% to 8.8% and 38.1% respectively. Conclusions. Pediatric HAART in limited resource settings often face difficulties to handle complex treatment schemes, but the implemented model seems to be an effective tool to reduce mortality rate in HIV positive pediatric population.
Marazzi, M.c., Germano, P., Liotta, G., Buonomo, E., Guidotti, G., Palombi, L., et al. (2006). Pediatric highly active antiretroviral therapy in Mozambique: An integrated model of care. MINERVA PEDIATRICA, 58(5), 483-490.
Pediatric highly active antiretroviral therapy in Mozambique: An integrated model of care
LIOTTA, GIUSEPPE;BUONOMO, ERSILIA;PALOMBI, LEONARDO;LIOTTA, GIUSEPPE
2006-01-01
Abstract
Aim. To test the impact of a public health model to implement HIV pediatric care in Limited Resource Settings. Methods. A retrospective study on the clinical files of 679 Mozambican children (mean age 4.4 years; SD 3.2), has been carried out. The pediatric patients received HAART (Highly Active Anti-Retroviral Therapy) in the framework of DREAM, a nationwide public health program offering an integrated model of care to HIV patients including free-of-charge HAART and monitoring, nutritional assessment and supplementation, peer-to-peer education, active tracing of the dropped out patients. Results. HAART was started in 297 subjects out of 679. The median time of treatment was 286 (IQ 25-75:125-465). Mortality rate was lower in the sub-sample receiving HAART (8.4%; CI 95%: 5.2-11.6 vs 13.1%; CI 95%: 9.7-16.5). After 6 months of treatment the percentage of viral load lower than 400 copies/mL rose from 4.9% to 46.3%. The percentage of patients with less than 15% of CD4 cells out of the total lymphocyte count and the percentage of patients below the -2 z-score decreased from 56.4% and 58.1% to 8.8% and 38.1% respectively. Conclusions. Pediatric HAART in limited resource settings often face difficulties to handle complex treatment schemes, but the implemented model seems to be an effective tool to reduce mortality rate in HIV positive pediatric population.Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons